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Abstract
Mutational signatures provide a powerful alternative for understanding the pathophysiology of cancer. Currently,
experimental efforts aimed at validating and understanding the etiologies of cancer-derived mutational signatures
are underway. In this review, we highlight key aspects of mutational signature experimental design and describe
the analytical framework. We suggest guidelines and quality control measures for handling whole-genome
sequencing data for mutational signature analyses and discuss pitfalls in interpretation. We envision that improved
next-generation sequencing technologies and molecular cell biology approaches will usher in the next generation
of studies into the etiologies and mechanisms of mutational patterns uncovered in cancers.
Introduction
Somatic mutations arising through cell-intrinsic and ex-
ogenous processes mark the genome with distinctive pat-
terns termed mutational signatures. The field began in
2012 with the demonstration of at least 5 such mutation
patterns in breast cancers [1]. Subsequently, 21 substitu-
tion signatures were identifiable across 30 cancer types
[2]. While there have been revisions of analytical compo-
nents of this field, there is a parallel trajectory evolving, fo-
cused on experimental validation, delineating aetiologies,
and mechanisms of mutagenesis. This is important, as the
field is quickly gaining traction in the clinical arena. To
provide the required confidence that mutational signa-
tures can be utilised clinically, it is necessary to cultivate
supporting experimental evidence for mutational signa-
tures to serve as potential biomarkers.
Several experimental studies to validate mutational sig-
natures have been conducted, employing various model
systems including C. elegans, yeast, human cancer cell
lines, organoids, and human induced pluripotent stem
cells among others [3–14]. There exist differences in how
these studies were performed and how data were proc-
essed, analysed, and interpreted with different algorithms.
In this review, we present guidelines that we hope will
facilitate future experiments and analyses. We focus on
considerations in experimental design and on the com-
putational framework for data analysis in mutational sig-
nature studies, particularly in human cellular model
systems. We further discuss issues that need to be con-
templated when linking an environmental mutagen or a
DNA repair process to a mutational signature, which is
not as straightforward as may superficially seem.
Experimental considerations
Choice of cellular model system
Three critical points require consideration when choosing
a human cellular system for investigating mutagenesis: the
average ploidy, its genetic background (cancer versus non-
cancerous), and the likelihood of on-going mutagenesis.
Ideally, a cellular model with a diploid (or haploid)
genome should be sought. Gene editing a haploid or dip-
loid model is more efficient than editing a polyploid
model. Having a lower ploidy also results in greater pro-
portional representation of mutations that arise in next-
generation sequencing reads, increasing the sensitivity of
mutation detection (Fig. 1a). In a hyper-triploid (3n+)
cell line like HeLa, newly acquired somatic mutations
may be present in one allele out of three, reported in ~
33% of reads. By contrast, a diploid line would report
mutations with greater certainty, in ~ 50% of reads.
There is also the consideration of sequencing cost: to
achieve comparable sensitivity of mutation detection, se-
quencing a haploid line or an experimental model with a
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smaller genome (e.g. yeast) would be more affordable
than sequencing a diploid or polyploid human model
system.
Non-cancerous lines may be preferable because they
are less physiologically abnormal. They may have “stem-
ness” properties such as in induced pluripotent stem
cells (iPSCs) and embryonic stem cells (ESCs), or they
may have tissue-specific properties such as tissue-
derived organoids and retinal pigment epithelial (RPE1)
cells. Non-cancerous lines are, however, more challen-
ging to grow in culture and less tolerant of manipula-
tion. They may be less likely to manifest mutational
signatures because DNA repair and checkpoint pathways
are functioning appropriately (or more so), and are thus
less permissive for revealing mutagenesis. For example,
TP53-intact iPSCs do not tolerate double-strand breaks
(DSBs), tend to undergo apoptosis quickly, and do not
generate rearrangements patterns. Stem cells may also
have other physiological properties that effectively pro-
tect them in their “stemness” state, and this could have
consequences on the likely manifestation of DNA dam-
age, for example, biochemical inactivation of certain
drugs because of higher expression of metabolic en-
zymes or enhanced drug efflux because of higher expres-
sion of multifunctional efflux transporters [15, 16].
By contrast, cancer cell lines thrive in culture and will
more likely yield patterns of genomic instability. None-
theless, they often have severely abnormal physiological
backgrounds, a multitude of pathway abnormalities ac-
quired in vivo and ex vivo, and thereby carry highly dis-
arrayed genomes (Fig. 1b). Cancer cell lines derived
from patients with relapsed disease are likely to be even
more pathophysiologically awry, with effects on muta-
tional outcome [17]. Such lines will have been exposed
to a multitude of natural and iatrogenic insults, may
have highly disordered genomes, and been subjected to
extensive rounds of selection pressure promoting evolva-
bility within the cell population. This could culminate in
increased mutagenesis. Counterintuitively, it could also
result in reduced mutagenesis if the physiological com-
pensation to overcome selective pressure leads to
physiological shifts that tend to suppress DNA damage
[17]. The chosen biological model must also be
amenable to clonal expansion following single-cell
bottlenecking, and here, cancer cell lines tend to fare
better than immortalised normal cells.
Additionally, it is crucial to know whether a cell line
model already carries intrinsic, on-going mutagenesis
because profound intrinsic mutational patterns could
drown out the signals being sought. For instance, the
colorectal cancer cell line DLD-1 BRCA2KO—albeit a
bona fide mismatch repair-deficient cell line—is often
used as an HR-deficient model due to its BRCA2 knock-
out (KO) status. WGS of DLD-1 BRCA2KO cells, how-
ever, shows marked mutational signatures associated
with MMR deficiency (Fig. 1b), likely to obscure the sub-
tler signals from BRCA2 deficiency or anything else that
would be engineered into this model system.
Some mutagenesis experiments may require an on-
going mutational signature in order to dissect mecha-
nisms of mutation formation. In that instance, it would
be valuable to identify cell lines with an on-going signa-
ture of interest, and engineer perturbations to see how
the signature deviates from its intrinsic state.
In a proof-of-principle study, we demonstrated the
feasibility of recreating cancer mutational signatures
in vitro using CRISPR-Cas9 gene editing in a near-
haploid cell model system, HAP-1 [7]. This cell line has
a very low level of intrinsic mutagenesis, mainly -
associated with cell culture that results in C>A muta-
tions (Fig. 1b), thought to be caused by oxidative stress
[18, 19]. In contrast to cancer cell lines such as H1299,
MDA-MB-231, HeLa which have higher average ploidy,
HAP-1 is also near-haploid—thus, sequencing was more
affordable (only sequenced to 15×). That it has a
propensity to revert to a diploid state is however recog-
nised, and regular inspection must be implemented to
detect such a situation for long-term maintenance in
culture [20, 21].
To investigate mutagenesis in cellular models, an iso-
genic “grandparental” sample of the cellular model sys-
tem of choice should be used as the genetic reference
from which all parental clones are derived (Fig. 2). Here,
parental clones refer to a single-cell derived colony that
has been through a particular experimental process, such
as gene editing of a particular locus and then selected
for the desired feature (e.g. knockout of gene X) or ex-
posure to a genotoxin with recovery post-exposure.
(See figure on previous page.)
Fig. 1 Choice of cellular model systems. a Effect of cellular ploidy on the proportion of NGS reads representing variant alleles and on variant
allele fraction (VAF) distribution. Blue and yellow lines joined by a dotted line represent forward and reverse reads, respectively (only parts of pair-
end reads are shown). Horizontal red lines represent the position of a variant on the sequencing reads. b Genome plots and 96-bar plots
representing mutational profiles of different cell lines. Shown from the outermost rings (genome plots) moving inwards are (i) the karyotypic
ideogram; (ii) base substitutions, plotted as rainfall plots (log10 (intermutation distance) on the radial axis; dot colour: blue, C>A; black, C>G; red,
C>T; grey, T>A; green, T>C; pink, T>G); (iii) insertions shown as short green lines; (iv) deletions shown as short red lines; (v) major (green blocks,
gain) and minor (red blocks, loss) copy number alleles; and (vi) rearrangements shown as central lines (green, tandem duplications; red, deletions).
Mutation burdens in the genome plots are non-representative here as different cell lines have had different lengths of time in culture. CML, chronic
myelogenous leukaemia; hiPSC, human induced pluripotent stem cell ; HPV, human papillomavirus; NSCLC, non-small cell lung carcinoma
Koh et al. Genome Biology           (2020) 21:37 Page 3 of 13
Genetic manipulation to generate gene-edited parental
clones
Most mutational signatures extracted from cancers are
associated with either exogenous mutagen exposures
(e.g. signature 7 with UV; signature 22 with aristolochic
acid I) or dysregulation of key DNA repair/replication
genes (e.g. signature 3 with BRCA1/BRCA2 mutations;
signature 10 with POLE mutations). One of the most
straightforward experimental strategies to explore muta-
tional signatures is therefore to knock out a gene of
interest, knock in an activating mutation, or overexpress
a particular protein, to see if the genetic manipulation
instigates mutagenesis.
To generate knockouts, aliquots of cells are exposed to
reagents designed to target genes of interest. Negative
editing controls should be included in parallel experi-
ments, in which cells receive no manipulations or non-
targeting versions of the gRNA. These controls are in-
formative of background and/or intrinsic mutagenesis
inherent to the cell line models. Following enrichment
of edited cells by selection markers—most commonly in
the form of a fluorescence reporter or an antibiotic re-
sistance gene—multiple single-cell edited clones can be
isolated and screened. Those carrying desired mutations
in the given gene are designated parental clones (Fig. 2a).
In scenarios where an empty vector or a scrambled
gRNA control is unavailable, a clone that has been
through targeting for gene knockouts but has neverthe-
less survived without biallelic alteration in the given
gene could be used as the “wildtype” control.
In a knockout or knockdown experiment, loss or
downregulation of the proposed target can be ascer-
tained through the confirmation of protein loss via west-
ern blot or mass spectrometry [22]. Functional assays
may be performed—for example, RAD51 formation
assay for an HR gene knockout, although the directness
of these relationships is often assumed.
Once verified, parental clones are cultured for a desig-
nated period to allow for mutation accumulation
(Fig. 2a). The time required for mutation accumulation
may vary between targeted genes and would need to be
determined empirically, striking a balance between the
time in culture and the cost of the experiment.
Some gene KOs may not produce discernible muta-
tional signatures owing to low rates of mutagenesis
under standard cell culture conditions. Artificially indu-
cing DNA damage such as with cisplatin could magnify
mutagenesis beyond its intrinsic baseline mutation rate,
increasing the likelihood of uncovering a signature. It
could, however, produce a non-physiological pattern be-
cause of the exogenous stressor, and thus, interpretation
of such patterns should be made with the experimental
set-up in mind. Using alternative isogenic models that
are more permissive for mutagenesis (e.g. mouse
Fig. 2 Experimental designs. a An example of a genetic manipulation experiment to link specific gene edit to mutational patterns. Note that upon parental
clone derivation, mutations might accumulate over several cellular generations to reveal mutational patterns. The number of doublings (n) required for
mutation accumulation is gene- and/or model system-specific. b An example of a genotoxin treatment experiment to link specific genotoxin exposure to
mutational patterns. Here, mutations accumulate as a result of treatment; treated cells (and controls) are effectively the parental clones. Repeated cycles of
treatment following recovery may help amplify the signals by increasing the mutation burden. It is imperative to sequence grandparental clones as the
normal genetic reference. The background mutagenesis can be determined through the control subclones
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embryonic fibroblasts, chicken DT40 lymphoblast cell
line, or cancer cell lines) may increase mutation rates
[23–28]. However, using different cell-based systems of
different species or with different genetic backgrounds
could result in diverse mutational signatures and must
be taken into consideration when interpreting data. For
example, cyclophosphamide and cisplatin signatures in
DT40 are different from those observed in human cellu-
lar models [28].
Genotoxin exposure
To interrogate mutational signatures associated with ex-
posure to environmental mutagens or genotoxins, aliquots
of an isogenic cell line are treated with the chemical in
question (Fig. 2b). Appropriate solvent controls must be
considered. For example, cisplatin stock should be consti-
tuted in 0.9% NaCl instead of DMSO as the latter could
cause ligand displacement and reduce cytotoxic effects of
the compound. Furthermore, when treated with cisplatin,
cells should be treated with 0.9% NaCl in a parallel control
experiment to detect potential mutagenesis incurred by
the solvent. In addition, many compounds are pro-
mutagens and require cytochrome P450-mediated meta-
bolic activation into DNA-reactive intermediates to exert
DNA damaging effects. Accordingly, when using these
mutagens, the experiments could be performed in the ab-
sence and presence of an exogenous metabolising system
such as the S9 rodent liver-derived metabolic enzyme
mixture with the mutagen of interest [8].
Treating cells with either a chronic, low-dose or punc-
tuated, high-dose exposure becomes another point to
consider. Typically, half-maximal inhibitory concentra-
tion (i.e. IC50 dose) of a compound is used as a starting
point. In a previous study, we treated human iPSCs with
79 environmental mutagens using doses corresponding
to either the IC50s or IC80s of the compounds for 2 to
24 h, followed by single-cell bottleneck subcloning upon
treatment recovery [8]. Notably, these cells were only
treated once. Repeated cycles of treatment following
recovery could conceivably increase mutation burden.
Selection of resistant clones might, however, develop
during a chronic experimental process and needs to be
considered particularly if no signatures are seen when
they were expected.
Following treatment, successful DNA damage induc-
tion is most commonly confirmed via immunofluores-
cence staining or western blotting of DNA damage
response proteins. Routinely, gH2Ax, phospho-p53,
phospho-p21, pRPA, pATM, and pATR are used as
markers for confirming DNA damage and DNA damage
response (DDR) signalling. Nevertheless, successful
DNA damage induction does not always correlate with
mutagenic outcome; the reverse is also true [8]. For in-
stance, formaldehyde treatment does not induce
detectable DDR signalling in human iPSC cells but is as-
sociated with a mutation pattern, whereas acetaldehyde
and acrylamide are able to elicit DDR, but do not pro-
duce detectable mutation patterns [8]. Thus, DDR in-
duction does not necessarily predict mutagenesis.
Mutation accumulation phase
To detect mutation patterns in experiments involving
gene editing, the parental clone is grown under standard
culture conditions, for an empirically determined num-
ber of cell doublings to allow for mutations to accrue at
a steady state (Fig. 2a). For accurate estimation of muta-
tion rate per cellular division, proliferation assays could
be considered to determine the doubling time of the
parental clones. For experiments involving exposure to
environmental mutagens or protein overexpression, mu-
tations accumulate as a consequence of the exposure.
Cells are usually given time to recover post-exposure.
At the end of the mutation accumulation phase, the
parental cell population will have increased in size and
be polyclonal, meaning that each cell will carry its own
set of mutations, although some very early, shared muta-
tions may be present. Thus, it is necessary to perform a
single-cell subcloning step at the end of mutation accu-
mulation in the parental clone (Fig. 2).
Single-cell bottleneck
Following the expansion of parental clones, multiple
single-cell subclones can be derived through limiting di-
lution or fluorescence-activated cell sorting with a flow
cytometer (FACS). This single-cell bottleneck is neces-
sary to permit detecting mutagenesis that has arisen in
individual cells in the parental population using current
sequencing technologies. Multiple subclones are re-
quired for each gene edit or treatment condition, and
serve as technical replicates, permitting assessment of
the consistency of mutational signatures between differ-
ent subclones. Generally, we find that sequencing more
replicate subclones (≥ 3) provides greater discriminatory
power to discern mutational signatures than increasing
mutation accumulation time in culture.
To ensure subclones are derived from a single cell, cel-
lular isolation can be monitored real-time using live-cell
analysis systems such as an IncuCyte. If a live-cell stain
(e.g. Calcein) is used, single-cell sorted culture plates can
be imaged with fluorescence microscopy to confirm that
each well only contains a single cell.
Subclones are expanded in culture until sufficient cell
numbers are reached for WGS without PCR amplifica-
tion. For customary 30-fold WGS, approximately 250–
500 ng of genomic DNA is required. A diploid human
cell contains roughly 6 pg of genomic DNA. Thus, ap-
proximately 100,000 cells are needed for whole-genome
sequencing a sample.
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Computational analysis
WGS is performed on single-cell derived subclones fol-
lowing mutation accumulation. The grandparental sam-
ple is used as the genetic reference to subtract variants
that have arisen prior to the grandparental sample and
to subtract all shared variants in the parental samples.
This allows detection of new (de novo) mutations that
arise as a consequence of experimental manipulation.
Alternatively, parental clones can also be used as a refer-
ence, although this would incur extra sequencing costs
as many additional parental clones would need to be
sequenced.
After obtaining WGS, short-read sequences of all sam-
ples are independently aligned to the reference genome.
All classes of somatic mutations are called in subclones
against the parental/grandparental clone. In the follow-
ing section, we demonstrate the use of WGS data for
assessing the quality of and relationships between ex-
perimental samples and for determining experimentally
derived mutational signatures.
Quality control
To ensure the observed mutational signatures are cor-
rectly associated with the proposed experimental condi-
tions, several essential quality control steps may be
implemented (Fig. 3a).
First, WGS offers a rapid, straightforward way of
checking the genotype of an edited cell line. Successful
CRISPR-Cas9 editing of a gene should result in
short indels near the gRNA-targeted sequence for a
knockout.
Similarly, off-target effects can be detected by expli-
citly seeking frameshift indels and large structural vari-
ants in the rest of the genome. Potential off-target sites
for a given gRNA sequence can be queried by using rele-
vant bioinformatic tools, e.g. COSMID (http://crispr.
bme.gatech.edu) [29] and WGE (https://www.sanger.ac.
uk/htgt/wge/) [30]. Unintended edits might affect a crit-
ical gene and result in unexpected mutator phenotypes.
Moreover, it is important to ensure that the model
system remains stable and does not develop overt malig-
nant potential through the experimental process. As a
rule of thumb, chromosome copy number in all sub-
clones should remain relatively unchanged from their
parent unless the treatment or edits are expected to
generate copy number variation. Evidence of selection,
including clonal and subclonal mutations in all DNA re-
pair genes and TP53, and driver amplifications should
remain absent from all samples. To ensure that experi-
mentally generated signatures are not a consequence of
another genetic defect acquired during culture or treat-
ment, mutations in coding sequences that could influ-
ence mutational outcomes should be sought.
Second, variant allele fractions (VAFs) can be used to
ascertain whether subclones were derived from single
cells. For a single-cell derived sample, all acquired muta-
tions should have VAFs of ~ 0.5 in a diploid model be-
cause they are present on one of two possible alleles in a
heterozygous state (Fig. 1a). Likewise, for haploid and
triploid cells, the VAFs are expected to be normally dis-
tributed around 1 and 0.33, respectively. Deviation of
VAF distribution from the expected may indicate impur-
ity of single-cell isolation (Fig. 3a). Critically, polyclonal
or mosaic subclones often show lower average VAFs and
falsely elevated mutation burdens, resulting in an over-
estimation of mutation numbers. Including these sam-
ples in the quantitative analysis will likely confound the
estimation of mutation rate and burden associated with
a particular experimental condition. Nevertheless, poly-
clonality most often does not alter the mutational profile
of subclones, as the patterns may be qualitatively identi-
cal even if the quantitative burden of mutations is
inaccurate.
Lastly, the likelihood of laboratory errors increases
when multiple experimental conditions are investigated
simultaneously. To uncover laboratory mix-ups, rela-
tionships between parental clones and their respective
subclones can be inspected to detect potential mislabel-
ling of subclones. As all subclones are originally derived
from their parental clones, all mutations detected in par-
ental clones should be present in their respective sub-
clones, but not in subclones derived from other parents.
Based on this genetic concept of relatedness, surveying
shared mutations among all samples would enable the
identification of mislabelled samples (Fig. 3b) [31].
Signature channels
Each mutation type (substitution, double substitution,
indel, rearrangement) has its distinct set of channels that
are used to define signatures. While it would be ideal to
have identical channels for experimental data and
cancer-derived data, this is not always possible because
the burden of mutagenesis can vary greatly between ex-
perimental model systems. The ratio of mutations to sig-
nature channels is important to consider: too many
channels for low yield of mutations will dilute any signal;
likewise, too few channels may not offer the resolution
required for deriving biological insights. Substitution
channels of experimental models tend to be identical to
the ones used for cancers. Indel and rearrangement
channels tend to be collapsed into fewer channels. To
make a comparison with cancer-derived signatures, it is
more effective to collapse cancer-derived signatures into
the same channels as the experiments rather than
stretching the experimental channels to suit the cancer
channels.
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Substitution channels mirror that which is customarily
used in literature. Sequence context immediately 5′ and
3′ to each mutated base is taken into consideration.
Since there are 6 classes of base substitution (C>A, C>G,
C>T, T>A, T>C, T>G) and 16 possible sequence con-
texts for each mutated base (5′ A, C, G, or T and 3′ A,
C, G, or T), there are 96 possible channels for substitu-
tion signature. Double substitutions are two adjacent
Fig. 3 Quality control (QC) of WGS data. a Using WGS data to perform QC on experimental samples. b Using shared variants between parental
and daughter subclones to identify relationships between samples. Three scenarios are presented. The upper panel shows two histograms per
experiment, with the total number of mutations per sample (horizontal histogram) and shared mutations between samples (vertical histogram, in
decreasing order). Subclones and parental clones for each scenario are also noted. Subclones that share mutations are dotted black and
connected with a line. The lower panel depicts hypothetical experiments. A red arrow indicates shared mutations between daughter subclones
and parental clones. Scenario 1: all subclones are correctly derived from the same parental clone as they share mutations among themselves and
with their designated parent, and also have unique mutations. Scenario 2: all subclones are derived from the same parental clone as they share
high numbers of mutations among themselves but not with the sequenced parent. In this example, an incorrect parental clone (purple) has been
sequenced. Scenario 3: subclones are derived from a mixed parental population. Not all subclones share a high number of mutations among
themselves and with their sequenced parent. Subclones 1, 4, and 6 are likely from one lineage; subclones 2, 3, and 5 are from a different lineage.
Note that clonal expansion for isolated daughter subclones is not depicted in the diagram for simplicity
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bases that are mutated, indicating the existence of com-
monly occurring mutagenic events that cause substitu-
tion mutation at neighbouring bases. Double
substitution signatures can be defined by 78 strand-
agnostic combinations [8, 32]. Here, the 5′ and 3′ se-
quence contexts are not commonly considered because
it creates (4 × 78 × 4 = 1248) too many channels for the
yield of double substitutions typically seen in a sample
(often < 5 in untreated samples).
Channels for small indels (< 100 bp) generally incorp-
orate the class (deletion versus insertion), motif CG/TA
content, and size (1 bp or larger), as well as the nature of
flanking sequence at the indel junction: repeat-mediated
indels resulting from replication strand slippage or
microhomology-mediated indels formed during the
repair of DNA double-strand breaks, or none. If poly-
nucleotide repeats flank the motif, the length of the re-
petitive sequence is also often considered. In some
instances, the variation of indel classifications might be
insightful in revealing the underlying mutagenesis pat-
terns. For example, for mutagens that are known to
affect particular nucleotide preferentially, it might be
valuable to extend the indel classification to consider the
effect of sequence context [8].
Rearrangement signatures are broadly categorised based
on four types of rearrangements, namely tandem duplica-
tions, deletions, inversions, and translocations, with further
consideration of sizes of the rearranged fragments [7].
An analytical framework to identify mutational signatures
By comparing the mutational burdens and profiles of ex-
perimental subclones with controls, experimental condi-
tions that effectively produce signatures can be identified.
The determination of experimentally generated muta-
tional signatures may vary depending on experimental set-
tings, but a general workflow encompasses: (1) identifying
background/intrinsic signatures in the chosen cellular sys-
tem; (2) detecting a quantitative difference in mutation
counts between experimental subclones and controls, as
well as a qualitative difference in the mutational spectra
between experimental subclones and controls; (3) sub-
tracting background/intrinsic signatures to obtain experi-
mentally associated signatures; and (4) evaluating the
stability of extracted mutational signatures (Fig. 4).
Pervasive intrinsic signatures may be distinctive in dif-
ferent cell lines. Growing cells in culture also contributes
substantial DNA damage that results in particular
patterns (Fig. 1b). These two potential sources of back-
ground mutagenesis are not negligible; thus, it is necessary
to identify and subtract them to determine experimentally
generated mutational signatures. In practice, the averaged
mutation burden and profile of control subclones can be
used to represent the background or intrinsic mutagenesis
of the chosen cellular system.
The mutational profile of experimental cells is a linear
combination of the mutational signature of background
mutagenesis and the pertinent experimental manipula-
tion. In principle, if a particular manipulation, whether
mutagen treatment or gene edit, generates mutational
signatures, one would expect additional mutagenesis
above background mutagenesis (Fig. 4). To determine
whether there is a significant quantitative increase of
mutation numbers in experimental subclones compared
to control, bootstrap resampling techniques can be used
to construct an “expected” distribution of mutation bur-
dens of control subclones. The likelihood (p value) of
observing a significantly different mutation burden for
experimentally generated subclones can thus be calcu-
lated through a permutation test (Fig. 5a).
To ascertain whether there are qualitative differences
in mutation profile between experimental subclones
and controls, the distinction between mutation profiles
can be measured by the signal-to-noise ratio (SNR)
(Fig. 5b). The Euclidean distance between the muta-
tional profiles of experimental versus control subclones
defines the “signal”, while the variability of mutation
profiles among subclones defines the “noise” parameter.
A large SNR value indicates that the difference of muta-
tional profiles between experimental subclones and
controls is sufficiently distinguishable from their noises,
and therefore, the experiment-associated signature may
be separated from the background signature with rela-
tive ease. If there is inadequate number of controls for
constructing a prior distribution, alternative methods
including clustering approaches (e.g. tSNE or contrast-
ive PCA) can be used to identify treated subclones that
are distinct from controls. Notably, the number of sub-
clones per experiment and the burden of mutation as-
sociated with each experiment are critical to the
robustness of the results.
The experiment-associated mutational signature can
then be obtained by subtracting the background muta-
tional signature from the mutational profile of treated
subclones (Fig. 4b). To do so, each experimental sub-
clone is bootstrapped to generate a distribution of muta-
tion numbers for each signature channel. Based on this
distribution, the upper and lower boundaries (99% confi-
dence interval, CI) of mutation numbers for each
channel can be calculated. Likewise, a bootstrapped
background signature profile can also be generated using
the averaged mutation profile and mutation counts. This
background can then be subtracted from the centroid of
the bootstrapped experimental subclone profiles. This
may result in negative values for some channels. How-
ever, as long as the numbers fall within the 99% CI of
the channels, negative values can be set to zero. Other-
wise, the initial background mutation burden has to be
reduced.
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Ideally, mutational signatures extracted from sub-
clones of the same parental clone should be consistent
(Fig. 4b). However, variation may be observed among
subclones, particularly when the experiments only incur
low mutation burden. The stability of a mutational sig-
nature can be reported by calculating the cosine similar-
ity between signatures extracted from subclones. Higher
cosine similarity (e.g. > 0.9) lends confidence to the ac-
curacy of extracted mutational signatures.
Discussion and perspective
As an increasing number of mutational signatures in cancers
are being brought to light, studies offering experimental val-
idation have also emerged.
Fig. 4 Principles of extracting mutational signatures from experimental samples. a Mutation burdens and profiles of human iPSCs treated with
different environmental mutagens. Treatments that generate a mutational signature typically show increased mutation burdens and/or altered
mutational profiles in the subclones compared to control (background). Note that effect sizes vary for different perturbations. b Determining
experimentally generated mutational signatures
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Association, not causation
There remains a need for some caution in interpretation,
even of experimental data. A particular perturbation
such as treatment with a chemical, for example, 5-
fluorouracil (5-FU) may produce a signature that we rec-
ognise [12]. In this case, signature 17, characterised by
T>G mutations, widely reported in cancers, of hitherto
unknown aetiology. It would, however, not necessarily
follow that 5-FU directly causes signature 17. Signa-
ture 17 is observed across a broad spectrum of pri-
mary tumours that have never been treated with 5-FU
and arises spontaneously in untreated mouse embry-
onic fibroblasts [33–36]. It is far more likely that 5-
FU is one of many compounds or physiological
stressors of the cell, which, in order to survive, re-
quires a physiological adaptation that results in this
hypermutator signature phenotype. In other words,
the signature is a secondary, indirect effect of the
treatment [37, 38]. These possibilities must be taken
into consideration when interpreting signature data,
regardless of whether experimental or cancer-derived.
As an interesting example, the current COSMIC sig-
nature 11, characterised by C>T transitions, was pre-
viously attributed to temozolomide because the
signature was enriched in tumours of patients that
had been treated with this alkylating agent [2]. How-
ever, systematic studies using the family of alkylating
agents on human IPSCs suggest that the signature of
temozolomide is defined by T>C mutations. Another
alkylating compound, 1,2-DMH, is instead similar to
signature 11 [8, 39].
Fitting of a priori signatures
Attributing aetiologies to mutational signatures is not as
straightforward as may superficially seem. Supervised fit-
ting of signatures could lead to falsely suggested rela-
tionships. When we take a set of allegedly “known
signatures” and ask the question which of those signa-
tures are present in a new dataset, this process, called
“fitting”, is purely mathematical. Presented with 20 po-
tential signatures, the algorithm will do its best to fit all
20 signatures to the data, regardless of whether they are
biologically present or not. Thus, presenting signatures
that may not be present in a sample but asking the algo-
rithm to fit it to the best of its ability could result in
reporting of biological processes that are not present in
the sample.
Fig. 5 Computational characterisation of experimentally generated mutational signatures. a Determination of quantitative difference (i.e. mutation
number increase) between experimentally generated subclones and controls through a permutation test based on the distribution of baseline
mutation burden in control subclones (orange). A p value≤ 0.01 indicates significantly different mutation burden for experimentally generated
subclones (red). b Schematic illustration of the distinction of mutational spectra between control and experimental subclones using the signal-to-
noise ratio (SNR). Here, μControl and μExp denote the means of the mutational profiles of control subclones and experimental subclones,
respectively; σControl and σExp denote the standard deviations of the mutation profiles of control and experimental subclones, respectively. In this
example, subclones of experimental condition B can be more confidently separated from the control subclones
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A particularly notorious example is the finding of the
“smoking signature” or signature 4 in a variety of differ-
ent tumour types, even when it is unlikely that tobacco
carcinogens could reach said tissue (e.g. prostate). That
is because signature 4 is dominated by C>A/G>T trans-
versions and many other signatures also have similar
C>A/G>T mutations. The fitting algorithm invokes sig-
nature 4 in tissues that have C>A/G>T mutations be-
cause it is such a strong phenotype.
Fitting other previously known signatures on experi-
mental data would incur similar risks.
Using cosine similarity
Mathematically, cosine similarity measures the similarity
between two vectors, in this case, the resemblance be-
tween two multichannel mutation profiles. However, it
does not measure similarity equally across all signatures,
working best for sparsely populated signatures that have
prominent features (i.e. prominent peaks), and less effect-
ively for flatter, nondescript profiles. Cosine similarity is
also not a linear metric—a measure of 0.8, for example,
does not imply a high level of correlation. While a meas-
ure of 0.99, by contrast, does imply a high level of correl-
ation, it does not mean that they are the same or caused
by the same mechanisms. Likewise, the same gene defect
or exposure can cause slightly different mutational signa-
tures in different tissues, cautioning against the blind reli-
ance on this metric to assess the similarity between
signatures.
Signatures and aetiologies do not necessarily have 1-to-1
mappings
Some experiments can induce multiple signatures per
treatment or knockout. If these signatures arise in differ-
ent classes, they are immediately interpretable as distinct
signatures of different classes. However, if a gene defect
produces multiple mutational signatures of the same
mutation class, it will not be possible to distinguish them
from each other instantly. Additional genetic or physio-
logical stressors may be required to separate two signa-
tures of the same mutation class.
Disparate mutational processes can also produce the
same mutational signature outcome. For example, a clas-
sical T>A mutation signature that has been associated
with aristolochic acid I is nearly identical to the T>A
signature induced by Dibenzo[a]pyrene Diol-epoxide
(DBPDE), a polycyclic aromatic hydrocarbon that is
present in tobacco smoke [8]. These disparate compounds
likely converge on the genome in the same way, producing
an adduct on adenine that results in a similar outcome.
This surprising, humbling result is one that underscores
the reason why we cannot simply assume that we under-
stand the full picture based on performing correlative
genomic analyses alone. Fundamentally, a 1-to-1 mapping
of one gene to one signature or one mutagen to one signa-
ture is unlikely to be the norm.
Signal sizes
The mutation burden generated by different environ-
mental mutagens and different gene knockouts is highly
variable. In general, mutagenesis is more pronounced in
experiments where external genotoxins are introduced.
Notably, many mutagens or gene knockouts do not pro-
duce a detectable increase in mutation burden in experi-
mental systems; their signal sizes can be much smaller
than observed in human cancers. Several possible rea-
sons might account for this. First, the cellular system of
choice may have a genetic background that suppresses
DNA damage. Second, excessive or lethal DNA damage
might cause apoptosis in normal cells, e.g. TP53-intact
iPSCs do not produce rearrangement signatures. Third,
the culture time and proliferation rate of the cell might
affect the rate of mutation accumulation and therefore
the signal size. Fourth, there is genetic redundancy of
DNA repair in the cell. As a result, some DNA repair
gene knockouts may not produce a direct mutational
consequence. Fifth, some DNA repair pathways mainly
target damage caused by external environmental muta-
gens, e.g. xeroderma pigmentosum (XP) genes of nucleo-
tide excision repair are involved in repairing UV-
induced cyclobutane pyrimidine dimers (CPDs). In
normal cell culture condition (no UV radiation), XP
gene knockouts indeed do not generate mutational
signatures.
Caution in using experimentally generated signatures
Environmental exposures that were the earliest to be as-
sociated with patterns in human cancers, well before the
advent of whole-genome sequencing such as the signa-
tures associated with tobacco, aristolochic acid, and
ultraviolet light, are precisely the experimental treat-
ments with the largest signals. They are orders of magni-
tude higher in mutagenicity compared to many other
mutagens and hence were readily detected in many dif-
ferent experimental models historically. We observed
smaller signals from exposures that have weaker DNA
damaging impact.
In seeking new “environmental causes of cancer”, we
must do so with some caution: Just because we now
know the signatures associated with these other agents,
does not mean that we can and should use all of these
signatures in an a priori way to seek out new causes of
cancer in all future cancer datasets. Some thoughtful
consideration is required. As mentioned previously,
when using a set of a priori signatures, this purely math-
ematical step is designed to seek out all possible
suggested signatures in the dataset, regardless of whether
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they are genuinely biologically there or not. Thus, we
caution the (mis) use of experimentally generated (or
any) mutational signatures—poorly considered use of
signatures during the fitting step could result in mis-
takenly interpreting the presence of an environmental
mutagen when it is not in a new dataset. Indeed,
mis-assigning the presence of an occupational muta-
gen, for example, could lead to legal claims that are
inappropriate.
Future directions in understanding mechanism
Future studies to explore mutagenesis by inducing specific
types of DNA damage in selective DNA repair defective gen-
etic backgrounds represent an attractive avenue to fine-tune
our understanding of and to gain further insights into the
mechanisms of mutagenesis. To achieve that, direct,
genome-wide unbiased and specific measurement of the
DNA lesions and their repair is required. For example, by
coupling Damage-seq with XR-seq for cisplatin damage [40–
42] or DSBCapture seq [43] with whole-genome sequencing
for DSBs, one could map precisely where the damage occurs
in the genome and chart how cells differentially repair or
misrepair the induced damage in different parts of the gen-
ome. Dissecting these mechanisms will help us understand
the regional heterogeneity in damage sensitivity and the ac-
cessibility and efficacy of DNA repair machinery.
Decreased sequencing cost and technical advances in
single-cell WGS, as well as long-read sequencing tech-
nologies (e.g. PacBio sequencing), will likely transform
the field. Long-read sequencing could uncover more and
resolve previously understudied large and complex
structural variants [44]; single-cell WGS would allow
tens and hundreds of cells to be profiled in a single ex-
periment, hence offering more statistical power while at
the same time simplifying the experiments by circum-
navigating the need for single-cell bottlenecking. Cur-
rently, single-cell WGS data still suffer from high levels
of noise and artefact variants introduced during whole-
genome amplification and cell lysis process [4]. When
more single-cell WGS data become available, such arte-
factual signatures may be better defined and used for fil-
tering out false-positive mutations.
We hope the guidelines presented here could help
streamline the design and analysis of future studies.
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